KA101 outperforms other clinical adjuvants in inducing balanced Th1/Th2 immunity and robust B cell responses to varicella-zoster virus glycoprotein E - Takeaways - MDSpire

KA101 outperforms other clinical adjuvants in inducing balanced Th1/Th2 immunity and robust B cell responses to varicella-zoster virus glycoprotein E

  • By

  • Yaru Quan

  • Su Zhang

  • Wenwen Wang

  • Yiping Wang

  • Kangwei Xu

  • Kaiqin Wang

  • Wenyan Wan

  • Jiaojiao Nie

  • July 16, 2026

Share

  • 1

    KA101, a liposomal adjuvant, demonstrated superior efficacy in promoting balanced Th1/Th2 immune responses against VZV glycoprotein E.

  • 2

    Distinct adjuvants shape adaptive immune responses through different innate immune activation patterns in a mouse model.

  • 3

    Traditional adjuvants like aluminum hydroxide and MF59 primarily induce Th2-biased immunity with limited cellular activation.

  • 4

    KA101 enhanced germinal center reactions, diversified the B-cell repertoire, and supported long-term immune memory.

  • 5

    The study provides insights into adjuvant-antigen interactions, aiding the development of next-generation herpes zoster vaccines.

Original Source(s)

KA101 outperforms other clinical adjuvants in inducing balanced Th1/Th2 immunity and robust B cell responses to varicella-zoster virus glycoprotein E

  • by Yaru Quan, Su Zhang, Wenwen Wang, Yiping Wang, Kangwei Xu, Kaiqin Wang, Wenyan Wan, Jiaojiao Nie

  • July 16, 2026

Related Content

Single-cell transcriptomic profiling of bronchial lymph nodes reveals mechanisms of PRRSV escape from host adaptive immunity

Human epidermal resident memory T cells: beyond the dermal perspective

The regulatory mechanisms and translational applications of non-coding RNA in SARS-CoV-2 infection-related cardiovascular pathology